IRWD logo

IRWD
Ironwood Pharmaceuticals Inc - Ordinary Shares - Class A

2,638
Mkt Cap
$645.28M
Volume
1.94M
52W High
$5.78
52W Low
$0.5616
PE Ratio
6.56
IRWD Fundamentals
Price
$3.92
Prev Close
$3.85
Open
$3.86
50D MA
$3.80
Beta
0.84
Avg. Volume
1.72M
EPS (Annual)
$0.1474
P/B
-2.97
Rev/Employee
$2.96M
$931.60
Loading...
Loading...
News
all
press releases
Ironwood Stock Down Despite Q1 Earnings and Revenue Beat
IRWD beats Q1 earnings and revenue estimates with Linzess sales surging on strong demand, but shares slide despite better-than-expected results.
News Placeholder
More News
News Placeholder
Ironwood Pharmaceuticals (IRWD) Tops Q1 Earnings and Revenue Estimates
Ironwood (IRWD) delivered earnings and revenue surprises of +242.86% and +44.26%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing lifechanging therapies for people living with gastrointestinal (GI) and rare diseases, today...
News Placeholder
Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, presented...
News Placeholder
Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its first quarter 2026 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 7, 2026...
News Placeholder
Ironwood Pharmaceuticals (IRWD) Projected to Post Earnings on Wednesday
Ironwood Pharmaceuticals (NASDAQ:IRWD) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-ironwood-pharmaceuticals-inc-stock...
News Placeholder
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Up 7.3% - Here's What Happened
Ironwood Pharmaceuticals (NASDAQ:IRWD) Trading 7.3% Higher - What's Next...
News Placeholder
Zacks Research Has Bearish Estimate for IRWD Q2 Earnings
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Analysts at Zacks Research cut their Q2 2026 earnings per share estimates for Ironwood Pharmaceuticals in a research note issued on...
News Placeholder
Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week 2026
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, announced...
News Placeholder
Zacks Research Issues Positive Outlook for IRWD Earnings
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Equities researchers at Zacks Research upped their Q4 2026 earnings per share estimates for Ironwood Pharmaceuticals in a note issued to...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available